Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments
Addition of clinical research and strategic partnership teams marks another milestone for Qbtech in North America, bolstering the company's regional capabilities and footprint
HOUSTON, June 02, 2025--(BUSINESS WIRE)--Qbtech, the global leader in objective ADHD testing, announces the formation of its Houston-based clinical research and strategic partnership teams, along with new staff appointments and promotions at the company's US headquarters. The employee expansions bolster the company's continued growth in the region, enhancing its capabilities and market presence as it continues to develop and enhance its software solutions.
Former clinical research manager Ragini Sanyal has been promoted to Head of Clinical Research, with Jonas Bäckström joining as Chief Strategic Partnership Officer and Jack Smith as Head of US Commercial Operations.
As Head of Clinical Research, Sanyal will lead the formalized clinical research team and its efforts to study the clinical utility and validity of objective ADHD assessments for diagnosing ADHD and its benefits in post-treatment follow-up.
"I truly believe objective ADHD technology is a guiding light through the uncertainty of the mental health space. I'm so excited to take on this role and lead our newly structured clinical research team to curate and share the data behind our objective assessments and how they can be used to progress ADHD care," says Sanyal. "This new team structure allows us to streamline our efforts across clinical operations, data management, medical writing, and trial execution. It will also help simplify decision-making, improve cross-functional collaboration, and provide a clearer focus as we continue to expand both our team and our portfolio. Coming off the World Congress on ADHD, I am so proud that our team was able to present four meaningful posters, and I can only imagine what we will accomplish in the coming months and years."
Jonas Bäckström, a former member of Qbtech's Board of Directors, has joined as Chief Strategic Partnership Officer, leading the newly established partnerships department from the Houston office. He brings a strong background in digital innovation, having worked with a pioneering digital healthcare provider in Sweden prior to joining Qbtech.
"This is an exciting opportunity for both me and Qbtech," says Bäckström. "I look forward to focusing on building scalable, evidence-based business models in the ADHD space and linking telehealth innovation with clinical, payer, and employer ecosystems. With my experience in business development and digital health, I am eager to help our partners achieve sustainable growth, improve patient outcomes, and shape a smarter, more accountable future for mental health, starting with ADHD."
Jack Smith will serve as Head of US Commercial Operations, leading efforts across sales and clinical support to drive Qbtech's expansion and identify new growth opportunities. A military veteran, Smith has served in various roles within the healthcare industry for more than 25 years.
"I'm thrilled to be joining Qbtech at such a pivotal time in the US ADHD market. My goal is to build a world-class sales team that delivers real value to clinicians by driving improved patient outcomes through objective, evidence-based tools," says Smith. "As awareness grows and underserved markets expand, we have a unique opportunity to empower physicians with the confidence they need to make accurate ADHD diagnoses."
The Qbtech team plans to hire additional staff in the Houston office throughout the year. Available career opportunities can be found at careers.qbtech.com.
About Qbtech
Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit www.qbtech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528695760/en/
Contacts
Media Contact: Hilari Barton, Trevelino/KellerHnbarton@trevelinokeller.com 404-214-0722 x 130
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Fortrea Holdings Inc. (FTRE) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fortrea Holdings Inc. ('Fortrea' or the 'Company') (NASDAQ: FTRE) securities between , inclusive (the 'Class Period'). Fortrea investors have until August 1, 2025 to file a lead plaintiff motion. What Happened? On September 25, 2024, the investment bank Jefferies downgraded Fortrea from buy to hold, citing perceived weaknesses in the Company's business model as a contract research organization ('CRO') amid pressure on biotechnology funding and that the cost savings Fortrea expects to achieve by existing transition services agreements ('TSAs') are 'not as material as one might think.' On this news, Fortrea's stock price fell $2.73, or 12.3%, to close at $19.48 per share on September 25, 2024, thereby injuring investors. Then, on December 6, 2024, Baird Equity Research stated that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]' On this news, Fortrea's stock price fell $1.90, or 8.1%, to close at $21.67 per share on December 6, 2024. Then, on March 3, 2025, before the market opened, Fortrea announced financial results for the fourth quarter and full year 2024, revealing the Company had missed its previously announced guidance for revenue and adjusted EBITDA for the full year 2024. The Company's financial results revealed full year adjusted EBITDA of $202.5 million, well below the Company's previously announced guidance of $220 million to $240 million. The Company also revealed full year revenue of $2.696 billion, which missed previously announced guidance of $2.7 billion to $2.725 billion. The Company further revealed financial guidance for the full year 2025, which projected declines in revenue and adjusted EBITDA, with revenues of $2.450 billion to $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million. Thomas Pike ('Pike'), the Company's then-Chief Executive Officer ('CEO'), explained that 'full-service work for projects from the pre-spin period,' 'have less revenue and less profitability' and 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' Pike further revealed 'this older versus newer mix issue will continue to negatively impact our financial performance during 2025.' On this news, Fortrea shares fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Fortrea securities during the Class Period, you may move the Court no later than August 1, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
26 minutes ago
- Yahoo
Cigna, Allegheny Health Network contract dispute threatens in-network access for thousands
Thousands of Cigna commercially insured people in the Pittsburgh region could lose in-network access to Allegheny Health Network by the end of June in a dispute over a new contract. AHN patients who use Cigna were notified this week of the impasse in negotiations on a new contract, meaning most care would be out of network if there isn't a new contract in place by June 30, according to a copy of a letter obtained by the Pittsburgh Business Times. About 20,000 Cigna members have used an AHN provider within the past year. It's the second such dispute in the past two years. The contract that runs out is for commercially insured members and not for Medicare or Medicare Advantage members. Cigna in March 2025 sold the Medicare-related business to Health Care Service Corp., a Chicago-based insurer. HCSC's coverage of Medicare and Medicare Advantage patients isn't impacted by this dispute and those patients will continue to have in-network access to AHN no matter what happens to the commercial insurance agreement. Click here to read more from our partners at the Pittsburgh Business Times. Download the FREE WPXI News app for breaking news alerts. Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Business Wire
27 minutes ago
- Business Wire
SSR Mining Announces Temporary Suspension of Operations at Seabee Due to Power Interruptions Caused by Forest Fires
DENVER--(BUSINESS WIRE)--SSR Mining Inc. (Nasdaq/TSX: SSRM) ('SSR Mining' or the 'Company') announces that operations at Seabee have been temporarily suspended due to power interruptions caused by forest fires in the vicinity of the mine. The forest fires are currently located approximately 15 kilometers to the north of the site. At this stage, the fire does not pose an immediate threat to site and infrastructure, however normal-course safety precautions are being taken to ensure the safety of our staff. Further updates will be provided as necessary. About SSR Mining SSR Mining is listed under the ticker symbol SSRM on the Nasdaq and the TSX. For more information, please visit:
